PD1

Phase 2Small molecule

Innovent Biologics (Suzhou) Co. Ltd.

PD1 is one of 35 small molecule programs targeting Hepatocellular Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hepatocellular CarcinomaRecruiting

Recurrent Rectal CancerRecruiting

Hepatocellular CarcinomaPreclinical

Recruiting

Recurrent Rectal CancerPhase 2

Recruiting

Competition

Competitive Landscape

265 competitors in Hepatocellular Carcinoma

#DrugCompanyPhaseTrials

Ibrance

Pfizer

Preclinical

1 2

Viread

Gilead

Preclinical

1 3

Sovaldi

Gilead

Preclinical

1 4

Cysteine Hydrochloride

Novartis

Preclinical

1 5

Hepsera

Coreg

2 7

PD1

Innovent Biologics (Suzhou) Co. Ltd.

Phase 2

1 8

Doptelet

AAkarx

Preclinical

1 9

Miraclid

TTechpool Bio-Pharma Co., Ltd.

Preclinical

1 10

Vermox

WWim Janssens

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Recurrent Rectal Cancer

NCT06767007

Q2 2029

PreclinicalRecruiting

Hepatocellular Carcinoma

NCT07479485

Clinical

Trials by Indication[1]

Lymphoma1 trial

Efficacy and Safety Evaluation of IBI308 in Treatment of Patients With Relapsed/Refractory Classical Hodgkin's Lymphoma

Completed· Innovent Biologics (Suzhou) Co. Ltd. logo

Innovent Biologics (Suzhou) Co. Ltd.·Phase 2·NCT03114683·96 enrolled

Recurrent Rectal Cancer1 trial

SBRT + PD-1 Antibody in Unresectable Locally Recurrent Rectal Cancer（SPARKLE）

Recruiting·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 2·NCT06767007·31 enrolled

Hepatocellular Carcinoma1 trial

An Open-Label, Multicenter, Phase I/II Study Evaluating MRG006A in Combination With Immune Checkpoint Inhibitors and Targeted Therapy in Patients With Advanced Hepatocellular Carcinoma

Recruiting·LLepu Biopharma Co., Ltd.·Preclinical·NCT07479485·160 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for PD1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PD1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PD1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Innovent Biologics (Suzhou) Co. Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Innovent Biologics (Suzhou) Co. Ltd.

PD1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2029

Trials by Indication[1]

Lymphoma1 trial

Recurrent Rectal Cancer1 trial

Hepatocellular Carcinoma1 trial

References

Drug Info

Quick Facts

Related News